Can neural autoantibodies be both a sign of injury and a contributor to dysfunction?

Neural autoantibodies can be both a downstream sign of neural injury and, in selected settings, a contributor to dysfunction. Their clinical meaning depends on antibody specificity, target accessibility, specimen source, assay validity, and concordance with the neurologic syndrome—not simply whether a panel is positive.

Injury-associated antibodies

• Serial human traumatic brain injury studies show that neural-reactive antibodies can increase after injury. Anti-GFAP antibodies rose by day 7 after severe TBI, and larger responses were associated with worse 6-month outcomes. Other moderate-to-severe TBI cohorts found broad immunoglobulin reactivity from the acute phase through months or years, including reactivity to MAG and blood–brain-barrier proteins.
• Release of neural antigens and blood–brain-barrier disruption offer plausible mechanisms for exposure or amplification of autoreactivity. These observations do not, however, establish that a detected antibody is itself causing ongoing neural damage.

Mechanistic relevance

• Surface and synaptic antibodies can be directly functional if they reach their intact neuronal targets. Anti-NMDAR antibodies, for example, cross-link GluN1-containing receptors, drive receptor internalization, reduce synaptic NMDAR signaling, and produce disease-relevant effects in passive-transfer models.
• This logic does not extend uniformly to intracellular-antigen antibodies. Anti-Hu or anti-Yo antibodies generally cannot bind their intracellular targets in intact neurons and more often mark a cytotoxic T-cell-associated immune process than direct antibody-mediated injury.

Clinical interpretation

• In 486 specimens sent for autoimmune encephalopathy, epilepsy, or dementia panels, 12% were positive, but only 2% of all tests were true positives (overall positive predictive value 17%). Positivity alone therefore cannot establish cause.
• Interpretation requires a compatible phenotype, supportive CSF/MRI or inflammatory findings, exclusion of alternatives, paired serum–CSF testing, and orthogonal confirmation of unexpected or discordant results. Isolated serum reactivity can be nonspecific, particularly in older adults.

Bottom line

• Antibody panels identify an immunologic clue, not causality: antibodies may follow injury, or—when directed at accessible neural surface targets—contribute to dysfunction.